Watch the event'Scale it up! Supercharging Britains Scientific Breakthroughs' at The Science MuseumThank you to our panellists for a great debate on how the UK can help support more UK innovation to become world-leading companies at our Scale it up! event at Londons Science Museum on 16 May.
We need long-term capital and people that will stay on the journey to ensure that academics create world-changing inventions, and the UK can reap the benefits."
Hosted by IP Group's Dr Sam Williams, our panel comprised British space scientist Dr Maggie Aderin-Pocock, former Chair of the Vaccine Taskforce, Dame Kate Bingham, Chairman of First Light Fusion, Bart Markus, CEO of Genomics plc, Professor Sir Peter Donnelly and IP Groups CEO Greg Smith.
Watch the event highlightsOXCCU raises $22m Series A roundPortfolio company OXCCU, a leading carbon-to-value company converting carbon dioxide and hydrogen into industrial and consumer products, has completed a US $22.7m Series A financing to commercialise cost-effective sustainable aviation fuel (SAF). The round was led by Clean Energy Ventures with participation from investors Aramco Ventures; Eni Next, the corporate venture arm of Italian energy company Eni; United Airlines Ventures Sustainable Flight FundSM; and Braavos Capital alongside existing investor Kiko Ventures (IP Groups cleantech investment platform), and University of Oxford. Trafigura, TechEnergy Ventures and Doral Energy-Tech Ventures also participated in the financing. Leveraging the funding, OXCCU plans to accelerate its path to market by scaling its catalytic approach to convert hydrogen and carbon dioxide into SAF and other sustainable fuels.
Read moreResseptor Therapeutics launches to develop new therapies for autoimmune diseases and cancerWe are excited to launch a new Australian biotech company, Resseptor Therapeutics, with an initial AU$2.25m investment to develop new therapies targeting autoimmune diseases and cancer. Resseptor aims to develop new therapies for inflammatory conditions based on novel technology that improves the way our immune system recognises and responds to tissues, malignancy, and pathogens.Read moreAccelerComm secures 21.5m Series B fundingOur portfolio company AccelerComm, which supercharges wireless communications networks with technologies that increase throughput and reduce latency, has closed 21.5m in Series B funding from Parkwalk, Swisscom and Hostplus together with participation from existing investors Bloc Ventures, IP Group and IQ Capital. The funding will be used to continue to expand the current team, drive US and global expansion, and develop the technology further.Read moreThe latest from ParkwalkOur Parkwalk Advisors team held their annual Meet the Portfolio event last month, featuring a number of companies from scalable quantum computing technology platforms and interactive injury rehabilitation systems, to autonomous driving development and graphene-based electronic devices.
Find out moreUpcoming EventsJoin us virtually on 2nd August 2023 for our IP Group Half Yearly Results Webinar. You can register on InvestorMeet here.See our events pageIn other news
- IP Group AGM statement - Read here
- Microbiotica announces clinical trial collaboration - Read here
- Quantum Motion Technologies raises 42m - Read here
- Mixergy secures 9.2m investment - Read here
- 3 Sisters Ventures Collective event sponsored by IP Group - Read here
IP Group plc
2nd Floor, 3 Pancras Square
Kings Cross
London N1C 4AGGET IN TOUCH
+44 (0)20 7444 0050
[email protected]
www.ipgroupplc.com
You are receiving this email because you have previously asked to receive updates from IP Group plc.
Our mailing address is:
IP Group plc2nd Floor, 3 Pancras SquareKings CrossLondon, N1C 4AGUnited Kingdom
Add us to your address book